Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1383 Preclinical characterization of D3L-002, a novel cancer immunotherapy bispecific antibody that elicits potent anti-tumor efficacy via co-blocking TIGIT and PVRIG
Compose a Response to This Article
Other responses
No responses have been published for this article.
